These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 23329400)

  • 1. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
    Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
    Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-antigen-binding bispecific antibodies for cancer treatment.
    Weidle UH; Kontermann RE; Brinkmann U
    Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.
    Fournier P; Schirrmacher V
    Clin Dev Immunol; 2010; 2010():423781. PubMed ID: 21403859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Int J Cancer; 2006 Feb; 118(3):658-67. PubMed ID: 16108015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.
    Zeidler R; Mysliwietz J; Csánady M; Walz A; Ziegler I; Schmitt B; Wollenberg B; Lindhofer H
    Br J Cancer; 2000 Jul; 83(2):261-6. PubMed ID: 10901380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi-specific antibody therapy for the treatment of cancer.
    Withoff S; Helfrich W; de Leij LF; Molema G
    Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
    Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
    Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.
    Cao Y; Axup JY; Ma JS; Wang RE; Choi S; Tardif V; Lim RK; Pugh HM; Lawson BR; Welzel G; Kazane SA; Sun Y; Tian F; Srinagesh S; Javahishvili T; Schultz PG; Kim CH
    Angew Chem Int Ed Engl; 2015 Jun; 54(24):7022-7. PubMed ID: 25919418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
    Haas C; Schirrmacher V
    Cancer Immunol Immunother; 1996 Nov; 43(3):190-4. PubMed ID: 9001573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
    Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
    Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.